MedTrace Logo

Study in Taiwanese Subjects Identified as CYP2C19 Poor and Extensive Metabolizers Receiving Rosuvastatin

NCT00766025 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2009-03-02

No results posted yet for this study

Summary

The main purpose of this study is to examine Taiwanese subjects identified as CYP2C19 poor and extensive metabolizers while taking single and multiple dosing a rosuvastatin calcium.

Conditions

  • CYP2C19 Poor
  • Extensive Metabolizers

Interventions

DRUG

Rosuvastatin Calcium

single oral dose on days 1, 4, 5, 6, 10-16, 17

Sponsors & Collaborators

Principal Investigators

  • Regeio Mosquea-Garcia, MD · AstraZeneca

  • Robin Meng, MD, PhD · AstraZeneca

  • Tzung-Dau Wang, MD · Northern Taiwan University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Completion
2009-02-28

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00766025 on ClinicalTrials.gov